Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first‐line sunitinib: a medical chart review across ten centers in five European countries by John, Wagstaff
ORIGINAL RESEARCH
Impact of adverse events, treatment modifications, and dose
intensity on survival among patients with advanced renal
cell carcinoma treated with first-line sunitinib: a medical
chart review across ten centers in five European countries
Camillo Porta1, Antonin Levy2, Robert Hawkins3, Daniel Castellano4, Joaquim Bellmunt5, Paul
Nathan6, Ray McDermott7, John Wagstaff8, Paul Donnellan9, John McCaffrey10, Francis Vekeman11,
Maureen P. Neary12, Jose Diaz12, Faisal Mehmud12 & Mei Sheng Duh13
1IRCCS San Matteo University Hospital Foundation, Pavia, Italy
2Institut Gustave Roussy, Paris, France
3School of Cancer and Imaging Sciences, University of Manchester, Manchester, United Kingdom
4Hospital 12 de Octubre, Madrid, Spain
5Hospital del Mar-IMIM, Barcelona, Spain
6Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom
7Adelaide & Meath Hospital, Tallaght, Dublin, Ireland
8South West Wales Cancer Institute, Singleton Hospital, Swansea, United Kingdom
9University College Hospital Galway, Galway, Ireland
10Mater Misericordiae Hospital, Dublin, Ireland
11Groupe d’analyse, Ltee, Montreal, Quebec, Canada
12GlaxoSmithKline, Collegeville, Pennsylvania
13Analysis Group, Inc., Boston, Massachusetts
Keywords
Angiogenesis, clinical observations, statistical
methods, urological oncology
Correspondence
Mei Sheng Duh, Analysis Group, Inc., 111
Huntington Avenue, Tenth Floor, Boston, MA
02199. Tel: 617 425 8131; Fax: 617 425
8001; E-mail: mduh@analysisgroup.com
Funding Information
This study was funded by GlaxoSmithKline
(GSK), Collegeville, PA. The funding from GSK
was not contingent upon the study results.
GSK participated in the study design, results
interpretation, and manuscript preparation as
reflected in the authorship by GSK employees.
The institutions where C. P., A. L., R. H., D. C.,
J. B., P. N., R. M., J. W., P. D., and J. M. are
employed have received research funds from
Analysis Group, Inc. F. V. and M. S. D. are
employees of Analysis Group, Inc., which has
received research grants from GSK.
Received: 20 February 2014; Revised: 17
June 2014; Accepted: 24 June 2014
Cancer Medicine 2014; 3(6): 1517–1526
doi: 10.1002/cam4.302
Abstract
Angiogenesis inhibitors have become standard of care for advanced and/or met-
astatic renal cell carcinoma (RCC), but data on the impact of adverse events
(AEs) and treatment modifications associated with these agents are limited.
Medical records were abstracted at 10 tertiary oncology centers in Europe for
291 patients ≥18 years old treated with sunitinib as first-line treatment for
advanced RCC (no prior systemic treatment for advanced disease). Logistic
regression models were estimated to compare dose intensity among patients
who did and did not experience AEs during the landmark periods (18, 24, and
30 weeks). Cox proportional hazard models were used to explore the possible
relationship of low-dose intensity (defined using thresholds of 0.7, 0.8, and 0.9)
and treatment modifications during the landmark periods to survival. 64.4% to
67.9% of patients treated with sunitinib reported at least one AE of any grade,
and approximately 10% of patients experienced at least one severe (grade 3 or
4) AE. Patients reporting severe AEs were statistically significantly more likely
to have dose intensities below either 0.8 or 0.9. Dose intensity below 0.7 and
dose discontinuation during all landmark periods were statistically significantly
associated with shorter survival time. This study of advanced RCC patients trea-
ted with sunitinib in Europe found a significant relationship between AEs and
dose intensity. It also found correlations between dose intensity and shorter
survival, and between dose discontinuation and shorter survival. These results
confirm the importance of tolerable treatment and maintaining dose intensity.
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Renal cell carcinoma (RCC) is the most common cancer
of the kidney, with 30% of patients presenting with meta-
static disease. Because RCC is highly resistant to chemo-
therapy, treatment options have been limited. Cytokines
(e.g., interleukin-2 or interferon alpha) have been widely
used as first-line treatment for advanced or metastatic
RCC, but have low-response rate, coupled with relevant
toxicity; furthermore, they do not have a survival benefit
for patients with disease of intermediate prognosis [1].
More recently, antiangiogenesis agents have been used as
alternative treatment. One such agent, Sutent (sunitinib
malate), received accelerated approval from the Food and
Drug Administration (FDA) for treatment of advanced
RCC in January 2006 [2].
However, safety data from both clinical trials and the
expanded access program (EAP) for sunitinib demon-
strated that adverse events (AEs) are common among
patients undergoing this treatment [3–5]. More recent data
suggest an emerging role for immunotherapy using the new
approach targeting the immune check point in RCC [6].
The objective of this study was to assess the relationships
between AEs and treatment patterns as well as between
treatment patterns and survival among patients with
advanced RCC receiving first-line sunitinib in real-world
clinical practice. First, we tested whether there is an associa-
tion between AEs and dose intensity among patients
receiving sunitinib as first-line treatment. Second, we inves-
tigated whether an association exists between dose intensity
and overall survival (OS). Third, we measured the associa-
tion between treatment modifications due to AEs and OS.
Methods
Study design
A retrospective, open-cohort study was conducted using
data from medical records for a total of 291 eligible
patients with advanced RCC who received sunitinib in
major institutions with expertise in treatment of advanced
RCC across five European countries. Patients had no prior
systemic treatment for advanced disease. The observation
period for each patient started from the date of first suniti-
nib prescription to the earliest of date of death, last follow-
up date at the clinic, or date of medical record abstraction.
Patients continued to be followed if they switched to any
second-line or third-line anti-angiogenesis agents.
Study population
To become eligible for the study patients were required to
meet the following inclusion criteria: (1) have had a
confirmed histological and/or cytological diagnosis of
locally advanced or metastatic RCC; (2) 18 years old or
older at the time of confirmed diagnosis of advanced
RCC; (3) received at least 1 dose of oral sunitinib after 1
January 2005; (4) were treatment na€ıve for advanced dis-
ease (including angiogenesis inhibitor-na€ıve) prior to
receiving the first prescription for sunitinib, and (5) were
actively treated at the clinic to ensure complete longitudi-
nal data. Patients were excluded if their first angiogenesis
inhibitor treatment was initiated less than 3 months prior
to the start date of medical record data abstraction, which
varied across sites, to ensure adequate follow-up time.
Data source
Local institutional review board/ethics committee
approval was sought and obtained for the collection of
data from medical charts from 10 major treatment centers
for advanced RCC in five European countries. Data for
this study were derived from medical charts reviewed for
treatment provided between July 2008 and December
2010 from oncology treatment centers in France (Institut
Gustave Roussy), Ireland (Adelaide and Meath Hospital
Tallaght, Mater Misericordiae University Hospital, and
University College Hospital Galway), Italy (IRCCS Policli-
nico San Matteo), Spain (Hospital Universitario 12 de
Octubre, and Hospital del Mar), and the United Kingdom
(Mount Vernon Cancer Centre, South West Wales Cancer
Institute, and Christie Hospital NHS Trust). Medical
records from all patients who met the study criteria and
who had archived and accessible records were included in
the study. Medical records were retrospectively reviewed
and extracted by clinical personnel.
Data extracted from the medical records included but
were not limited to: date of initial advanced RCC diagno-
sis, demographic variables, comorbidities, prior pharma-
cological or radiological treatments, metastatic site(s),
drug-related adverse event data, laboratory data, and
radiologic test results. The dates of treatment initiation
and discontinuation, initial dosing, dates and reasons for
treatment interruptions and treatment changes, dosing
modifications, and follow-up tumor assessments were also
recorded.
Landmark periods
This study uses landmark analysis to assess the relation-
ship between treatment patterns and overall survival. A
landmark period is defined as a period of time following
treatment initiation during which an exposure of interest
is observed (e.g., AEs). Patients are then divided between
those with and without the exposure during the landmark
period and outcomes are compared from the end of the
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landmark period until the end of observation. In the cur-
rent study, a landmark period of 24 weeks following suni-
tinib treatment initiation was used and sensitivity analyses
using 18 and 30 weeks were also considered.
Event definitions
Adverse events
Study investigators at the clinics retrospectively assessed
toxicity experienced by patients while taking sunitinib
and graded the AEs using the National Cancer Institute
Common Terminology Criteria for AEs (CTCAE) version
3.0 [7]. If the severity of the AE was unknown then grade
1 was assigned. Only AEs experienced by patients during
their first-line sunitinib treatment were considered for the
assessment of safety.
Treatment modifications due to AEs
Treatment modifications included dose reductions, treat-
ment interruptions (temporary stoppage of treatment
with intent to resume treatment), and treatment discon-
tinuations. Reasons for treatment modifications were also
abstracted from patients’ medical records, and only modi-
fications that were responses to AEs were considered in
this analysis. Survival as measured from the end of the
landmark period was then compared between patients
with and without treatment modifications during the
landmark period.
Dose intensity
Dose intensity was calculated as the actual daily dose of
sunitinib received by patients divided by the optimal or
recommended daily dose. For example, suppose a patient
received a total of four cycles of 4 weeks treatment fol-
lowed by 2 weeks off (4/2), but after two cycles at 50 mg/
day, the dose was reduced to 37.5 mg/day. This patient’s
actual daily dose was 29.7 mg instead of the 33.3 mg rec-
ommended daily dose. The relative dose intensity of the
patient over these four cycles was therefore 89.1% [(29.7/
33.3) 9 100]. In addition to dose reductions and dose
interruptions, changes in treatment schedules, such as
moving from a continuous or 5/1 schedule to a 4/2 sche-
dule would influence dose intensity.
The impact of three thresholds of low-dose intensity
was explored: <70%, <80%, and <90%; these cutoffs were
prespecified as part of the study protocol. For the study
of the association between AEs and dose intensity, dose
intensity was measured from the end of the AE observa-
tion period (equivalent to the landmark period) until the
end of observation. For the study of the association
between dose intensity and OS, dose intensity was mea-
sured during the landmark period. Dose intensity for the
entire observation period was not considered in either
analysis given the study design and the need to assess
dose intensity as the outcome from the end of the AE
observation period for the analysis of the association
between AEs and dose intensity or as the exposure during
the landmark period for the analysis of the association
between dose intensity and OS.
Overall survival
Time to death was defined as the time from the end of
the landmark period to the date of death. Patients who
did not die by the study end date were censored at the
date of last follow-up. For the study of the association
between AEs and dose intensity, patients who died or had
their last follow-up date during the landmark period were
dropped from the sample analyzed. Similarly, for the OS
analyses, patients who died or had their last follow-up
date during the landmark period were dropped from the
sample analyzed.
Statistical analysis
Descriptive statistics were used to describe patient baseline
characteristics, AEs, dose intensity, and treatment modifi-
cations. Means, median, and ranges were used to describe
continuous variables; frequencies and percentages were
reported for categorical variables. The association between
AEs and different dose intensity thresholds was assessed
using a multivariate logistic regression model. In addition
to the indicator for AEs during the AE observation period,
other covariates considered in the model included age at
treatment initiation, number of metastatic sites, gender,
time from initial RCC diagnosis to initiation of first-line
sunitinib treatment, and country. The strength of associa-
tion between dose intensity or treatment modifications and
time to death was explored using multivariate Cox propor-
tional hazards regression models. The Cox regressions
included the same controls as the logistic regression model.
All analyses were performed using SAS software version 9.2
(SAS Institute, Inc., Cary, NC).
Results
Patient characteristics
A total of 291 patients in France (n = 65), Ireland
(n = 53), Italy (n = 15), Spain (n = 39), and the UK
(N = 119) received first-line sunitinib and met the eligi-
bility criteria for this study. Table 1 presents baseline
characteristics of the study population.
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Adverse events and dose intensities
Table 2 reports summary statistics on AEs and dose
intensities. Of the 184 patients with a sunitinib treatment
duration of at least 24 weeks, 125 (67.9%) reported at
least one AE of any grade, and 19 (10.3%) had at least
one grade 3 or 4 AE.
The average duration of sunitinib treatment beyond the
24-week observation period was 43.8 weeks. Mean dose
intensities were significantly different among patients who
did and did not report ≥1 grade 3 or 4 AE (≥1 grade 3 or
4 AE: 19; 0 grade 3 or 4 AE: 165, mean dose intensity:
0.748 vs. 0.869, 95% confidence interval [CI] of differ-
ence: [0.006, 0.237]), but were not significantly different
among patients who did and did not report ≥1 all grade
AE (≥1 AE: 125; 0 AE: 59, mean dose intensity: 0.837 vs.
0.891, 95% CI of difference: [0.013, 0.121]). Of the 184
patients observed during the 24-week AE observation per-
iod, 69 (37.5%), 60 (32.6%), and 35 (19.0%) had dose
intensities below 0.9, 0.8, and 0.7, respectively, for the
duration of treatment following the 24-week period.
Table 3 presents adjusted odds ratios quantifying the
strength of association between AEs and sunitinib low-
dose intensity. There was no statistically significant asso-
ciation between the development of an AE of any grade
within 24 weeks of treatment initiation and low-dose
intensity treatment following this period for all three
thresholds used to define low-dose intensity. Patients
with ≥1 grade 3 or 4 AE during the first 24 weeks of
treatment were 5.12 (95% CI: [1.27, 20.68]) times more
likely to have a dose intensity below 0.8 and 6.79 (95%
CI: [1.39, 33.26]) times more likely to have a dose
intensity below 90% following the AE observation per-
iod. Adverse event observation periods of 18 and
30 weeks produced similar results for both any grade
and grade 3 or 4.
Dose intensity and overall survival
Table 4 summarizes results from multivariate Cox pro-
portional hazard models assessing the association
between sunitinib dose intensity and survival. Of the 291
patients included in this study, 217 patients were taking
sunitinib and had not died at the end of the 24-week
landmark period. Sixty four (29.5%) of these patients
experienced at least one treatment modification (dose
reduction or treatment interruption) that led to a dose
intensity below 0.9 during the landmark period. Dose
intensities below 0.8 and 0.7 during the 24-week land-
mark period were observed in 34 (15.7%) and 15 (6.9%)
patients, respectively. The predominant initial dosing
schedule for sunitinib was 50 mg QD 4/2; overall, 81%
of patients initiated treatment with this schedule and the
proportion that initiated at this dose and schedule varied
from 66% to 100% in the five countries (data not
shown).
The median overall survival for the 291 patients who
had not died at the end of the 24-week landmark period
was 168.9 weeks. Figure 1 shows the Kaplan–Meier esti-
mates of OS by level of dose intensity during the 24-week
landmark period. After adjusting for potential confound-
ers, OS was significantly shorter among patients with a
sunitinib dose intensity below 0.7 (Hazard Ratio [HR]:
3.36, 95% CI: [1.49, 7.55]), but dose intensities below 0.8
and 0.9 were not associated with significantly shorter sur-
vival times following the 24-week landmark period. Simi-
larly, sunitinib low-dose intensity below 0.7 was
associated with significantly shorter OS when considering
landmark periods of 18 and 30 weeks, but no significant
associations were observed between OS and dose intensi-
ties below 0.8 and 0.9 during the same landmark periods.
Treatment modification and overall survival
Table 5 presents results from multivariate, Cox propor-
tional hazard models quantifying the association between
treatment modifications and OS. Of the 217 patients who
were taking sunitinib and had not died at the end of the
landmark period of 24 weeks, 12 (5.5%) had discontinued
treatment, 69 (31.8%) had ≥1 dose reduction, and 44
(20.3%) had ≥1 treatment interruption. Overall, 80
(36.9%) patients had experienced at least one treatment
Table 1. Baseline characteristics among patients with advanced RCC
treated with sunitinib as first-line angiogenesis inhibitor treatment.
Patients receiving sunitinib
N = 291
Age at treatment initiation, years
Median (range) 62.2 (25.9–88.6)
Mean (SD) 60.9 (12.0)
Male, n (%) 196 (67.4)












Time from initial RCC diagnosis to treatment, months
Mean (SD) 26.0 (39.7)
<1 year, n (%) 162 (55.7)
RCC, renal cell carcinoma; SD, standard deviation.
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modification due to AEs during the 24-week landmark
period.
After adjusting for potential confounders, overall sur-
vival was significantly shorter among patients who discon-
tinued treatment due to AEs within 24 weeks of initiation
(HR: 2.80, 95% CI: [1.06, 7.38]). Sunitinib treatment dis-
continuation within the first 18 and 30 weeks of therapy
initiation was also associated with significantly shorter
survival (18 weeks, HR: 4.91, 95% CI: [2.29, 10.54];
30 weeks, HR: 2.69, 95% CI: [1.05, 6.89]). Other treat-
ment modifications were not associated with significant
decrease in survival after adjusting for potential con-
founders.
Discussion
This study, which relied on data from medical charts
from 291 treatment-na€ıve patients across five countries in
Europe, contributes to the growing body of knowledge
regarding the tolerability and management of side effects
for patients receiving first-line anti-angiogenic agents for
the treatment of advanced RCC [4, 5, 7–15]. The findings
Table 2. Summary of adverse events and dose intensity among patients with advanced RCC treated with sunitinib as first-line angiogenesis inhib-
itor treatment.
AE observation period (landmark period)
18 weeks 24 weeks 30 weeks
Patients with treatment duration
exceeding the AE observation period N = 205 N = 184 N = 156
All grades AEs
≥1 AE, n (%)1 132 (64.4) 125 (67.9) 109 (69.9)
Most frequent AEs, n (%)
Fatigue/Asthenia 58 (28.3) 58 (31.5) 54 (34.6)
Mucositis/Stomatitis 51 (24.9) 51 (27.7) 51 (32.7)
Diarrhea 33 (16.1) 33 (17.9) 33 (21.2)
Nausea 27 (13.2) 26 (14.1) 26 (16.7)
Hand–foot syndrome 18 (8.8) 20 (10.9) 20 (12.8)
Skin rash 12 (5.9) 15 (8.2) 15 (9.6)
Grades 3 and 4 AEs
≥1 AE, n (%)2 19 (9.3) 19 (10.3) 14 (9.0)
Most frequent AEs, n (%)
Fatigue/Asthenia 5 (2.4) 5 (2.7) 5 (3.2)
Mucositis/Stomatitis 5 (2.4) 4 (2.2) 2 (1.3)
Diarrhea 2 (1.0) 2 (1.1) 2 (1.3)
Hand–foot syndrome 1 (0.5) 2 (1.1) 2 (1.3)
Pain 1 (0.5) 1 (0.5) 1 (0.6)
Thrombotic events 1 (0.5) 1 (0.5) 1 (0.6)
Duration of treatment beyond the AE
observation period, weeks, mean (SD)
44.9 (58.5) 43.8 (59.9) 44.9 (62.2)
Dose intensity3,4, mean (SD)
All grades AEs
No AE 0.887 (0.232) 0.891 (0.221) 0.878 (0.204)
≥1 AE 0.843 (0.253) 0.837 (0.250) 0.844 (0.243)
Grades 3 and 4 AEs
No AE 0.869 (0.248) 0.869 (0.239) 0.872 (0.224)
≥1 AE 0.771* (0.205) 0.748* (0.230) 0.689 (0.214)
Patients with low-dose intensity, n (%)3
<0.9 73 (35.6) 69 (37.5) 60 (38.5)
<0.8 64 (31.2) 60 (32.6) 50 (32.1)
<0.7 38 (18.5) 35 (19.0) 28 (17.9)
AE, adverse event; RCC, renal cell carcinoma; SD, standard deviation.
1Includes all patients with at least 1 AE during the respective AE observation period.
2Includes all patients with at least one grade 3/4 AEs during the respective AE observation period.
3Dose intensity calculated over the duration of treatment following the respective AE observation period.
4The “*” indicates that the mean dose intensity is statistically significantly different between the no AE and ≥1 AE groups at an a level of 0.05.
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from this study indicate that treatment-na€ıve patients
receiving first-line sunitinib experienced frequent AEs and
high rates of treatment modifications within the first few
months of treatment, leading to a suboptimal drug expo-
sure. Given the high rates of AEs reported among patients
taking sunitinib, the relationship between AEs and treat-
ment modifications, and the resulting observed associa-
tion on dose intensity and overall survival are important
considerations.
These findings are consistent with results from a
pharmacokinetic/pharmacodynamic meta-analysis investi-
gating the relationship between exposure to sunitinib
and efficacy and tolerability endpoints in patients with
cancer, including advanced RCC [16]. The authors
found that increased exposure to sunitinib was associ-
ated with longer time to progression, longer OS, a
higher probability of a response, and greater tumor size
decreases, thus recognizing the importance of avoiding
unscheduled dose titrations and treatment interruptions.
Increased exposure to sunitinib was also associated with
AEs, although these were generally mild to moderate in
severity [16]. Furthermore, the Renal EFFECT trial
found no benefit in efficacy or safety for sunitinib
37.5 mg/day given on a continuous daily dosing com-
pared with the approved intermittent schedule of
50 mg/day given on 4/2 cycles—corresponding to a
lower daily dosing of 33.3 mg—in patients with
advanced RCC [17]. The lack of recovery time from
sunitinib-related AEs could be hypothesized as a factor
explaining the absence of benefit in efficacy associated
with the increased exposure to sunitinib offered by the
37.5 mg continuous daily dosing.
Table 3. Association between adverse events and low-dose intensity in patients with advanced RCC treated with sunitinib as first-line angiogene-
sis inhibitor treatment1.
Odds ratio (95% CI)2
Low-dose intensity <0.7 Low-dose intensity <0.8 Low-dose intensity <0.9
All Grade AEs (reference: no AE)
AE within 18 weeks of treatment initiation 1.60 (0.65, 3.98) 1.56 (0.75, 3.24) 1.60 (0.80, 3.21)
AE within 24 weeks of treatment initiation 2.40 (0.80, 7.19) 1.71 (0.76, 3.83) 1.63 (0.76, 3.50)
AE within 30 weeks of treatment initiation 2.14 (0.63, 7.24) 1.83 (0.76, 4.40) 2.10 (0.90, 4.88)
Grades 3 and 4 AEs (reference: no grade 3/4 AE)
AE within 18 weeks of treatment initiation 5.12 (1.33, 19.71) 7.19 (1.44, 35.86) 5.61 (1.12, 28.09)
AE within 24 weeks of treatment initiation 3.18 (0.89, 11.36) 5.12 (1.27, 20.68) 6.79 (1.39, 33.26)
AE within 30 weeks of treatment initiation 2.09 (0.59, 7.39) 4.97 (1.39, 17.72) 8.75 (1.81, 42.21)
AE, adverse event; CI, confidence interval; RCC, renal cell carcinoma.
1Each model was adjusted for age at treatment initiation, number of metastatic sites, gender, time from initial RCC diagnosis to treatment, and
country.
2Confidence intervals are computed with robust standard errors clustered at the country level.
Table 4. Association between low-dose intensity and time to death in patients with advanced RCC treated with sunitinib as first-line angiogenesis
inhibitor treatment1.













N = 236 N = 217 N = 195
Low-dose Intensity <0.90 Yes: 64 No: 172 Yes: 64 No: 153 Yes: 59 No: 136
HR (95% CI) (reference: dose intensity ≥0.90) 0.94 (0.56, 1.58) 0.96 (0.56, 1.65) 1.30 (0.74, 2.29)
Low-dose Intensity <0.80 Yes: 33 No: 203 Yes: 34 No: 183 Yes: 37 No: 158
HR (95% CI) (reference: dose intensity ≥0.80) 1.75 (0.95, 3.23) 1.52 (0.82, 2.84) 1.20 (0.64, 2.23)
Low-dose Intensity <0.70 Yes: 15 No: 221 Yes: 15 No: 202 Yes: 15 No: 175
HR (95% CI) (reference: dose intensity ≥0.70) 2.31 (1.01, 5.28) 3.36 (1.49, 7.55) 2.53 (1.10, 5.79)
CI, confidence interval; HR, hazards ratio; RCC, renal cell carcinoma.
1Each model was also adjusted for age at treatment initiation, number of metastatic sites, gender, time from initial RCC diagnosis to treatment,
and country.
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The method used for this analysis determined rates of
specific AEs and treatment patterns following a particular
exposure of interest during a given period (landmark
period) following treatment initiation. Thus, results are
difficult to compare with that of the respective sunitinib
RCT and EAP [4, 5]. One would expect lower rates of
reported AEs in an observational study. Furthermore, by
design, only AEs among patients who lived until the end
Figure 1. Kaplan–Meier estimates of overall survival by level of dose intensity (landmark period: 0–24 weeks).
Table 5. Association between treatment modifications due to adverse events and time to death in patients with advanced RCC treated with suni-
tinib as first-line angiogenesis inhibitor treatment1.













N = 236 N = 217 N = 195
Discontinuation3 Yes: 14 No: 222 Yes: 12 No: 205 Yes: 14 No: 181
HR (95% CI) (reference: no discontinuation) 4.91 (2.29, 10.54) 2.80 (1.06, 7.38) 2.69 (1.05, 6.89)
Dose reduction4 Yes: 64 No: 172 Yes: 69 No: 148 Yes: 70 No: 125
HR (95% CI) (reference: no dose reduction) 1.07 (0.63, 1.82) 1.28 (0.75, 2.20) 1.14 (0.65, 1.98)
Dose Interruption5 Yes: 46 No: 190 Yes: 44 No: 173 Yes: 50 No: 145
HR (95% CI) (reference: no dose interruption) 1.50 (0.89, 2.52) 1.33 (0.77, 2.32) 1.61 (0.92, 2.82)
Any treatment modification6 Yes: 78 No: 158 Yes: 80 No: 137 Yes: 85 No: 110
HR (95% CI) (reference: no treatment modification) 1.18 (0.72, 1.91) 1.26 (0.75, 2.09) 1.38 (0.81, 2.36)
CI, confidence interval; HR, hazard ratio; RCC, renal cell carcinoma.
1Each model was also adjusted for age at treatment initiation, number of metastatic sites, gender, time from initial RCC diagnosis to treatment,
and country.
2Includes patients who experienced a treatment modification and did not die or who were not censored at any point during the respective land-
mark period.
3If a patient’s discontinuation date was not available and the patient died, treatment duration was calculated from treatment initiation to date of
death. If patient’s discontinuation date was not available and there was no record of patient death, treatment duration was calculated from treat-
ment initiation to date of last follow-up.
4If a patient experienced multiple dose reductions, only the first dose reduction was accounted for.
5If a patient experienced multiple dose interruptions, only the first dose interruption was accounted for.
6If a patient experienced multiple treatment modification, only the first modification was accounted for.
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of the landmark period are reported in the current study.
Similarly, RCTs and EAPs have well-defined protocol for
dose reduction as well as treatment interruption and dis-
continuation which may lead to distinctive treatment pat-
terns compared to those observed in real-world practice,
thus affecting dose intensity. In an EAP, the mean (SD)
relative dose intensity of sunitinib was 0.952 (0.253) [5],
which is higher than the mean dose intensity observed in
the current study beyond the AE observation period of
24 weeks (no AE: 0.845 [0.279; ≥1 AE: 0.837 [0.250]).
Regional differences in the availability of alternative
treatment options may influence sunitinib treatment pat-
terns and dose intensity and may have contributed to var-
iation within the current study’s population. For example,
in the UK, until 2010 sunitinib was the only drug recom-
mended for treatment of advanced RCC by the National
Institute for Health and Clinical Excellence and most pri-
mary care trusts did not fund other drugs for advanced
RCC [8]. In comparison, sunitinib, sorafenib, and bev-
acizumab were available and used in France and Ireland
at the time of the chart review abstraction. As such, the
proportion of patients experiencing sunitinib treatment
discontinuation was markedly lower in the UK compared
with France and Ireland (UK: 43.7%; France: 69.9%; Ire-
land: 69.8%) while the opposite trend was observed for
dose reduction (UK: 48.7%; France: 43.9%; Ireland:
34.0%) and treatment interruption (UK: 37.8%; France:
9.2%; Ireland: 35.8%). Corroborated by the longer med-
ian treatment duration observed in the UK (months, UK:
19.8; France 10.7; Ireland: 8.7), these results suggest that
physicians in the UK may try to keep patients on suniti-
nib for as long as possible while managing adverse reac-
tions with dose reductions and treatment interruption
given the lack of alternative options at the time. Thus, by
staying longer on sunitinib with more dose reductions
and interruptions, patients from the UK (N: 119; 40.9%)
may have contributed to lower the average dose intensity
of the study population.
The sample sizes for each country were too small to
conduct individual country-level analyses. With more data
such analyses may have been of interest as patients in the
UK, for example, were likely to maintain sunitinib treat-
ment for longer for reasons stated above. This longer
treatment duration could influence associations between
AEs and dose intensity, dose intensity and survival, and
treatment modification and survival. Despite not conduct-
ing individual country-level analyses, all multivariate
models in the current study were adjusted for country.
The specific results reported in this manuscript show the
measure of association and 95% CI for the main exposure
of interest and not for each factor included in the model.
However, when we examine the coefficients associated
with each country indicator for the analysis of the
association between AEs assessed at 24 weeks and low-dose
intensity we see that there are no significant associations
between specific countries and the outcome in the model
(low-dose intensity). No significant trend in country-
specific effects emerged in the other analyses as well.
This study raises questions regarding optimal dose
intensity which may be answered in future studies. The
current study examined the sequential association of AEs
during the early part of treatment (landmark period) and
subsequent dose intensity, and separately, the sequential
association of dose intensity during the early part of treat-
ment (landmark period) and death. Thus, with the cur-
rent data and analysis it is not possible to determine the
particular time point following an AE when the dose
intensity falls below a dosing point that compromises sur-
vival. However, it was determined in the current analysis
that the inflection point for survival was somewhere
between 70% and 80% dose intensity. A sensitivity
analysis was conducted to assess the association between
low-dose intensity during the landmark period and subse-
quent survival for those patients who later did and did
not discontinue sunitinib treatment as a way to evaluate
the impact of disease dissemination on survival. The asso-
ciation between low-dose intensity (<0.70) and survival
remained significant for patients who did later discon-
tinue sunitinib and was no longer significant for those
who did not later discontinue sunitinib. This finding may
indicate that survival differences by dose intensity during
the landmark period may be attributable to disseminated
disease subsequent to the suboptimal dose intensity as
patients with disseminated disease may be the ones to dis-
continue therapy.
Furthermore, future studies may consider additional
clinical endpoints of interest such as disease progression
and progression-free survival (PFS). The data for the cur-
rent study came from real-world, clinical practice, and
disease progression is not systematically measured and
reported in these settings, as it is in clinical trials. Thus,
in this context, the observed PFS is more a function of
when progression was assessed rather than when the
patient actually progressed. For that reason, the current
study does not assess PFS as an outcome. RCTs and
EAPs, which capture outcomes such as PFS systemati-
cally, have analyzed progression or PFS as the primary
endpoint for first-line treatment with sunitinib for
advanced RCC as subsequent-line therapies affect OS
[3–5, 17]. Second-line therapies may have had an impact
on the OS reported in the current study as 18% of the
patients included in the main analysis of the impact of
dose intensity on OS received second-line therapy.
Patients with a dose intensity less than 0.70 were more
likely than those with greater dose intensity to receive
second-line therapy (33% vs. 17%), so it is possible that
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the difference in second-line therapy between those with
low and non-low first-line sunitinib dose intensity con-
tributed to the observed difference in survival by dose
intensity. It is also possible that patients with low density
for first-line therapy could have been more like to pro-
gress, and therefore switch from first-line to second-line
therapy, and the progression may be associated with
shorter survival.
There are some limitations associated with this study.
This study used retrospectively collected data; occurrences
of AEs, treatment modifications, and outcome may have
been underreported. The reported AEs were likely to be
clinically significant AEs that required interventions. Real-
world clinical practice settings are likely to capture fewer
AEs in medical records compared with RCT settings
which have systematic procedures to capture AEs. If the
medical records in the current study were more likely to
include AEs which led to treatment modifications lower-
ing dose intensity then this could have biased the results
such that the association between AEs and lower dose
intensity is overestimated. Given the low number of
patients experiencing certain exposures of interest during
the landmark periods, there may have been insufficient
power to detect differences in outcomes between groups
in some analyses. It is not known whether any patients in
this study received sunitinib and interferon simulta-
neously. While this may have been unlikely, we cannot
preclude the possibility as the inclusion criteria were such
that patients received sunitinib as first-line therapy and
had no prior interferon. If some patients did receive
interferon treatment this may have contributed to some
AEs and associated treatment modifications, reducing
dose intensity. In addition, due to low sample counts, the
analyses did not distinguish between specific types of AEs,
such as fatigue, hand–foot syndrome, mucositis/stomati-
tis, and their association with dose intensity. Also,
adjusted analyses did not control for baseline Eastern
Cooperative Oncology Group (ECOG) performance score
as a large proportion of patients did not have baseline
scores available (≥55%). It should also be noted that this
study was performed using data collected from 10 tertiary
oncology centers in France, Ireland, Italy, Spain, and UK;
results may not be generalizable to community oncology
centers or other European countries where clinical prac-
tice may differ. Furthermore, while these analyses adjusted
for known confounders, imbalances in unobserved char-
acteristics influencing survival may be present, and these
were not adjusted for. Unobserved characteristics include
Memorial Sloan-Kettering Cancer Center (MSKCC) risk
groups, and prognostic factors reported by Heng et al.
[18]. such as hemoglobin and calcium levels, and neutro-
phil and platelet counts, Finally, as this is an observa-
tional study, it is important to stress that only statistical
correlations could be established which by no mean infers
the existence of causal relations.
This study provided evidence through a comprehensive
review of medical charts for 291 advanced RCC patients
across key institutions in five European countries that
severe AEs were significantly correlated with lower dose
intensities, and that AEs were frequently cited as reasons
for treatment modifications and discontinuations. This
study further showed that low-dose intensities and treat-
ment discontinuations were correlated with shorter sur-
vival times, indicating the importance of maintaining
dose intensity. These results suggest that the use of agents
with a better tolerability profile coupled with proper ther-
apy management including prevention, early recognition,
and prompt management of AEs may be important for
patients with advanced RCC.
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